Mark Schoenebaum

Schoenebaum: Biotech P/Es Show 'Buying Signal' With Caveat; Amgen, Biogen, Celgene & Gilead Have Catalysts

What It's Like To Have Dinner With BioMarin Executives

Evercore Breaks Down Regeneron's Q2 Report

What It's Like To Have Dinner With BioMarin Executives

Evercore Breaks Down Regeneron's Q2 Report

Evercore ISI's Mark Schoenebaum Comments On Zoetis' Q2 Call

Biogen's Final Catalyst Of 2015 Is A 'Coin Flip,' Evercore ISI Analyst Says

Evercore ISI's Mark Schoenebaum Comments On Zoetis' Q2 Call

Biogen's Final Catalyst Of 2015 Is A 'Coin Flip,' Evercore ISI Analyst Says

Analyst's Key Takeaways From Eli Lilly, Bristol-Myer Squibb's Latest Conference Calls

Celgene's Q2 Earnings Call: Highlights & Analyst Commentary

Mark Schoenebaum Recent News

Evercore ISI's Schoenebaum Breaks Down Celgene-Receptos Merger

Evercore ISI Analyst Gives Highlights From Vertex's Orkambi Call

AAIC Is Coming: Here's What To Expect, Biogen And Eli Lilly Investors

Evercore ISI Analyst Breaks Down Amgen's IPR Against AbbVie's Humira Formulation Patent

With Bristol-Myers Trial Stopped Early, 'What's Next?'

Gilead Sciences Earnings Preview: Hepatitis C Guidance Is Key

Evercore ISI Analyst: 160,000 Patients Affected by AbbVie Hepatitis Pact

ISI Says AstraZeneca Needs To 'Speak Up For Increased Bid'

Top Financial Tweets From February 11, 2014

Analysts Comment on Merck's Hep C Regiment Advances

ISI Group Believes That Genzyme Corporation (GENZ) Could Jump to $80

ISI Group Is Bullish On AMLN, HGSI, GENZ And DNDN

Deutsche Bank Analyst Likes Genzyme (GENZ), Gilead (GILD) And Amgen (AMGN)